Crossmark

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

Crossref DOI link: https://doi.org/10.1186/s12885-018-4108-0

Published Online: 2018-02-15

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Demuth, Christina

Madsen, Anne Tranberg

Weber, Britta

Wu, Lin

Meldgaard, Peter

Sorensen, Boe Sandahl
Funding

Funding for this research was provided by:

No Funding
More Information

Article History

Received: 1 September 2016

Accepted: 8 February 2018

First Online: 15 February 2018

Ethics approval and consent to participate

: All patients gave informed written consent and the project was in compliance with the Helsinki Declaration. The Central Denmark Region Committee on Biomedical Research Ethics approved the project (M-20080012).

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below